| Literature DB >> 32303161 |
Stefano Ballestri1, Claudio Tana1, Maria Di Girolamo1, Maria Cristina Fontana1, Mariano Capitelli1, Amedeo Lonardo1, Giorgio Cioni1.
Abstract
Nonalcoholic fatty liver disease (NAFLD) embraces histopathological entities ranging from the relatively benign simple steatosis to the progressive form nonalcoholic steatohepatitis (NASH), which is associated with fibrosis and an increased risk of progression to cirrhosis and hepatocellular carcinoma. NAFLD is the most common liver disease and is associated with extrahepatic comorbidities including a major cardiovascular disease burden. The non-invasive diagnosis of NAFLD and the identification of subjects at risk of progressive liver disease and cardio-metabolic complications are key in implementing personalized treatment schedules and follow-up strategies. In this review, we highlight the potential role of ultrasound semiquantitative scores for detecting and assessing steatosis severity, progression of NAFLD, and cardio-metabolic risk. Ultrasonographic scores of fatty liver severity act as sensors of cardio-metabolic health and may assist in selecting patients to submit to second-line non-invasive imaging techniques and/or liver biopsy. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Atherosclerosis; cardiometabolic risk; conventional ultrasound; hepatic fibrosis; hepatic steatosis; liver biopsy; metaboliczzm321990derangements.
Mesh:
Year: 2020 PMID: 32303161 DOI: 10.2174/1381612826666200417142444
Source DB: PubMed Journal: Curr Pharm Des ISSN: 1381-6128 Impact factor: 3.116